Trump Says He’s Taking Hydroxychloroquine Preventatively

SMG/Zuma

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to Mother Jones' newsletters.

For weeks, President Trump has been touting the anti-malarial medication hydroxychloroquine as a “miracle drug” for treating COVID-19. On Monday, he admitted that he has been taking it prophylactically for a week and a half.

“A lot of good things have come out about the hydroxy,” he said. “I happen to be taking it. I happen to be taking it.” 

Trump slipped the revelation in at the end of a “roundtable with restaurant executives and industry leaders” in which he railed against the whistleblower who revealed the Trump–Ukraine scandal and defended Secretary of State Mike Pompeo’s alleged habit of having a staffer perform household tasks. (Trump’s justification? “Maybe his wife isn’t there.”) But of all the absurd things Trump said, his purported use of a non-approved drug for an illness he doesn’t have takes the cake.

When asked for evidence of the drug’s efficacy, Trump replied, “Here’s my evidence: I get a lot of positive calls about it.” 

The drug, which is used to treat lupus and arthritis, has not been proven to be effective in treating COVID-19, though a clinical trial is underway. In an observational study of hospitalized COVID-19 patients published in the New England Journal of Medicine, researchers found that “hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death” and noted that randomized, controlled trials are still needed. The Food and Drug Administration has warned against its use outside of hospital settings.

Watch the video below:

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.